<div id="readability-page-1"><p>Edgestream Partners L.P. lessened its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 58.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,080 shares of the biopharmaceutical company's stock after selling 31,442 shares during the quarter. Edgestream Partners L.P.'s holdings in PTC Therapeutics were worth $675,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>PTC Therapeutics</strong> alerts:</span></p></div><p>Several other institutional investors have also recently made changes to their positions in the company. Choreo LLC raised its position in shares of PTC Therapeutics by 4.1% during the 2nd quarter. Choreo LLC now owns 11,426 shares of the biopharmaceutical company's stock valued at $356,000 after buying an additional 452 shares during the period. Arizona State Retirement System raised its position in PTC Therapeutics by 3.4% in the second quarter. Arizona State Retirement System now owns 19,301 shares of the biopharmaceutical company's stock valued at $590,000 after purchasing an additional 636 shares during the period. Diversified Trust Co raised its position in PTC Therapeutics by 5.6% in the second quarter. Diversified Trust Co now owns 15,317 shares of the biopharmaceutical company's stock valued at $468,000 after purchasing an additional 818 shares during the period. ProShare Advisors LLC raised its position in PTC Therapeutics by 9.3% in the first quarter. ProShare Advisors LLC now owns 18,313 shares of the biopharmaceutical company's stock valued at $533,000 after purchasing an additional 1,564 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new stake in PTC Therapeutics in the first quarter valued at approximately $46,000. </p><h2>PTC Therapeutics Trading Up 1.3 %</h2><p>Shares of PTCT stock opened at $36.64 on Friday. The firm has a fifty day moving average price of $33.41 and a 200 day moving average price of $32.43. The company has a market cap of $2.81 billion, a P/E ratio of -4.77 and a beta of 0.64. PTC Therapeutics, Inc. has a 12 month low of $17.53 and a 12 month high of $40.69. </p><p>PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.16). The company had revenue of $186.70 million for the quarter, compared to analysts' expectations of $192.12 million. On average, equities analysts forecast that PTC Therapeutics, Inc. will post -5.09 EPS for the current year. </p><h2>Insider Buying and Selling at PTC Therapeutics</h2><p>In other PTC Therapeutics news, CFO Pierre Gravier sold 2,269 shares of the company's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $34.02, for a total value of $77,191.38. Following the completion of the transaction, the chief financial officer now owns 53,531 shares in the company, valued at $1,821,124.62. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 5.50% of the stock is currently owned by insiders. </p><h2>Analysts Set New Price Targets</h2><p>A number of analysts have issued reports on the company. Barclays boosted their target price on PTC Therapeutics from $25.00 to $31.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday, August 9th. Robert W. Baird assumed coverage on PTC Therapeutics in a research report on Wednesday, September 4th. They issued an &#34;outperform&#34; rating and a $44.00 target price on the stock. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $64.00 target price on shares of PTC Therapeutics in a research report on Tuesday, September 17th. JPMorgan Chase &amp; Co. restated an &#34;overweight&#34; rating and issued a $53.00 price target on shares of PTC Therapeutics in a research note on Thursday, June 20th. Finally, The Goldman Sachs Group boosted their price target on shares of PTC Therapeutics from $18.00 to $32.00 and gave the stock a &#34;sell&#34; rating in a research note on Tuesday, May 28th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of &#34;Hold&#34; and a consensus price target of $37.64.</p><p><b>Check Out Our Latest Report on PTCT</b></p><h2>PTC Therapeutics Profile</h2> (Free Report)<p>PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.</p><h2>Read More</h2><ul><li>Five stocks we like better than PTC Therapeutics</li><li>Russell 2000 Index, How Investors Use it For Profitable Trading</li><li>Take Advantage of Village Farms Stock as Cannabis Market Evolves</li><li>What Are Dividends? Buy the Best Dividend Stocks</li><li>MarketBeat Week in Review – 9/16 - 9/20</li><li>ESG Stocks, What Investors Should Know</li><li>Don’t Miss These 3 Retail Stocks for Fall Gains</li></ul><p><strong>Want to see what other hedge funds are holding PTCT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRDVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ The $15 &#34;Insider Secret&#34; That Could Save Your Retirement <span><span>(From Behind the Markets)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx"/></p><h2>Should you invest $1,000 in PTC Therapeutics right now?</h2><p>Before you consider PTC Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PTC Therapeutics wasn't on the list.</p><p>While PTC Therapeutics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

PTCT

<p>Edgestream Partners L.P. reduced its stake in PTC Therapeutics, Inc. by 58.7% in Q2, now holding 22,080 shares. Other investors like Choreo LLC and Arizona State Retirement System also adjusted their positions. PTC Therapeutics shares rose 1.3% to $0.64, with a market cap of $1.81 billion. The company reported a loss of $0.16 EPS, missing estimates. Analysts have mixed ratings on the stock, with an average target price of $0.64.</p>

Edgestream Partners L.P. Trims Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)